UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
[X] Quarterly Report pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934 for the quarter ended
September 30, 1997
or
[_] Transition Report pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934 [No Fee Required] For the
transition period from _________ to __________
Commission File No. 0-19892
IBAH, Inc.
(Exact name of registrant as specified in its charter)
Delaware 52-1670189
-------- ----------
(State or other jurisdiction of I.R.S. Employer
incorporation or organization) Identification Number)
Four Valley Square, 512 Township Line Road, Blue Bell, Pennsylvania 19422
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (215) 283-0770
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, par value $.01 per share
(Title of Class)
Indicate by check mark whether the Registrant (1) has filed all reports to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes X No
--- ---
The aggregate market value of the voting stock held by non-affiliates of
the Registrant on November 7, 1997 was $60,000,000. For purposes of making this
declaration only, the Registrant has defined affiliates as including all
directors.
The number of outstanding shares of the Registrant's Common Stock, par
value $.01 per share, on November 7, 1997 was 23,244,152.
Part I - Financial Information
Item 1. Financial Statements
IBAH, INC. AND SUBSIDIARIES
---------------------------
CONSOLIDATED BALANCE SHEETS
---------------------------
(unaudited)
ASSETS December 31, September 30,
------ 1996 1997
----------------- -----------------
CURRENT ASSETS:
Cash and cash equivalents $ 15,588,000 $ 9,118,000
Short-term investments 5,235,000 1,398,000
Accounts receivable, net 27,614,000 38,202,000
Prepaid expenses and other 868,000 1,198,000
----------------- -----------------
Total current assets 49,305,000 49,916,000
PROPERTY AND EQUIPMENT, net 7,799,000 12,177,000
GOODWILL, net 34,571,000 33,888,000
OTHER ASSETS 451,000 331,000
----------------- -----------------
$ 92,126,000 $ 96,312,000
================= =================
LIABILITIES AND STOCKHOLDERS' EQUITY
------------------------------------
CURRENT LIABILITIES:
Current portion of long-term debt $ 1,376,000 $ 2,913,000
Accounts payable 3,497,000 3,462,000
Other accrued expenses 9,829,000 10,132,000
Payable to independent investigators 2,585,000 3,068,000
Deferred revenue 22,812,000 21,347,000
----------------- -----------------
Total current liabilities 40,099,000 40,922,000
----------------- -----------------
DEFERRED RENT 586,000 549,000
----------------- -----------------
LONG-TERM DEBT 1,885,000 5,799,000
----------------- -----------------
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Preferred stock, $.01 par value, 2,000,000 shares authorized,
749,665 shares issued and outstanding as of
December 31, 1996 and September 30, 1997 7,000 7,000
Common stock, $.01 par value, 50,000,000 shares authorized,
22,023,846 shares issued and outstanding as of December 31, 1996
and 23,234,754 shares issued and outstanding as of September 30, 1997 220,000 232,000
Additional paid-in capital 73,889,000 75,610,000
Accumulated deficit (24,793,000) (26,658,000)
Cumulative translation adjustment 233,000 (149,000)
----------------- -----------------
Total stockholders' equity 49,556,000 49,042,000
----------------- -----------------
$ 92,126,000 $96,312,000
================= =================
The accompanying notes are an integral part of these statements
-2-
IBAH, INC. AND SUBSIDIARIES
---------------------------
CONSOLIDATED STATEMENTS OF OPERATIONS
-------------------------------------
(unaudited)
For the Three Months Ended For the Nine Months Ended
September 30, September 30,
---------------------------------- ------------------------------------
1996 1997 1996 1997
--------------- ---------------- ---------------- -----------------
REVENUES $ 20,454,000 $ 33,575,000 $ 55,966,000 $ 91,513,000
Less- Reimbursed costs 5,369,000 10,511,000 14,302,000 28,144,000
--------------- ---------------- ---------------- -----------------
Net revenues 15,085,000 23,064,000 41,664,000 63,369,000
--------------- ---------------- ---------------- -----------------
OPERATING EXPENSES:
Direct 7,564,000 12,376,000 21,325,000 34,191,000
Selling, general and administrative 6,957,000 9,681,000 20,003,000 27,267,000
Restructuring costs - - - 1,078,000
Non-recurring item-Acquired
research and development 510,000 - 510,000 -
--------------- ---------------- ---------------- -----------------
Total operating expenses 15,031,000 22,057,000 41,838,000 62,536,000
--------------- ---------------- ---------------- -----------------
Operating income (loss) 54,000 1,007,000 (174,000) 833,000
MERGER COSTS - - - (176,000)
INTEREST INCOME, net of interest expense 161,000 (27,000) 299,000 266,000
--------------- ---------------- ---------------- -----------------
Income from continuing operations
before income taxes 215,000 980,000 125,000 923,000
INCOME TAXES - 271,000 - 763,000
--------------- ---------------- ---------------- -----------------
Income from continuing operations 215,000 709,000 125,000 160,000
LOSS FROM DISCONTINUED OPERATIONS, including
loss on disposal of $1,547,000 (175,000) - (175,000) (2,154,000)
--------------- ---------------- ---------------- -----------------
NET INCOME (LOSS) $ 40,000 $ 709,000 $ (50,000) $ (1,994,000)
=============== ================ ================ =================
NET INCOME (LOSS) PER SHARE--
CONTINUING OPERATIONS $ 0.01 $ 0.03 $ 0.01 $ 0.01
DISCONTINUED OPERATIONS (0.01) - (0.01) (0.10)
=============== ================ ================ =================
NET INCOME (LOSS) PER COMMON SHARE $ - $ 0.03 $ - $ (0.09)
=============== ================ ================ =================
WEIGHTED AVERAGE NUMBER OF
COMMON SHARES OUTSTANDING 25,083,000 27,460,000 17,031,000 22,825,000
=============== ================ ================ =================
The accompanying notes are an integral part of these Statements.
-3-
IBAH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
-------------------------------------
(unaudited)
For the Nine Months Ended
September 30,
-------------------------------------
1996 1997
------------------ ------------------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss $ (50,000) $ (1,994,000)
Adjustments to reconcile net loss to net cash
used in operating activities-
Depreciation and amortization 1,825,000 3,276,000
Deferred rent (74,000) (37,000)
Discontinued operations 175,000 2,154,000
Acquired research and development 510,000
Changes in assets and liabilities-
(Increase) decrease in-
Accounts receivable (4,209,000) (11,628,000)
Prepaid expenses and other (79,000) (1,240,000)
Increase (decrease) in-
Accounts payable and accrued expenses (93,000) (204,000)
Payables to independent investigators 1,134,000 537,000
Deferred revenue (3,404,000) (359,000)
------------ ------------
Net cash used in operating activities (4,265,000) (9,495,000)
------------ ------------
CASH FLOWS FROM INVESTING ACTIVITIES:
Redemption (purchases) of short-term investments (4,197,000) 3,837,000
Purchases of property and equipment (1,960,000) (6,422,000)
Net cash paid in business acquisitions - (209,000)
Net investing activity of discontinued operations - (146,000)
Other (81,000) (324,000)
------------ ------------
Net cash provided by (used in) investing activities (6,238,000) (3,264,000)
------------ ------------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock, net of expenses 18,263,000 1,532,000
Proceeds from issuance of debt, net of expenses 25,000 6,316,000
Payments on long-term debt (994,000) (1,098,000)
------------ ------------
Net cash provided by financing activities 17,294,000 6,750,000
------------ ------------
EFFECT OF EXCHANGE RATE CHANGES ON CASH (157,000) (461,000)
------------ ------------
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 6,634,000 (6,470,000)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 7,564,000 15,588,000
------------ ------------
CASH AND CASH EQUIVALENTS, END OF PERIOD $ 14,198,000 $ 9,118,000
============ ============
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid $ 244,000 $ 583,000
============ ============
Equipment acquired under capital lease obligations $ 495,000 $ 289,000
============ ============
The accompanying notes are an integral part of these statements.
- 4 -
IBAH, INC. AND SUBSIDIARIES
---------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
------------------------------------------------------
NOTE 1. BASIS OF PRESENTATION:
---------------------
There have been no material changes in accounting policies from those
stated in the Company's Annual Report on Form 10-K for the year ended December
31, 1996.
Certain information and footnote disclosures normally included in
financial statements prepared in accordance with generally accepted accounting
principles have been condensed or omitted. These consolidated financial
statements should be read in conjunction with the consolidated financial
statements and notes thereto included in the Company's Annual Report on Form
10-K for the year ended December 31, 1996. The statements for the periods ended
September 30, 1996 and 1997 are unaudited. However, in the opinion of the
Company, the statements reflect all adjustments of a normal and recurring nature
necessary for a fair presentation for such periods. Results of operations for
the three-month and nine-month periods are not necessarily indicative of the
results to be expected for any other interim period or for the year.
NOTE 2. PRINCIPLES OF CONSOLIDATION:
---------------------------
The consolidated financial statements include the accounts of IBAH, Inc.
and its subsidiaries. All material intercompany balances and transactions have
been eliminated.
NOTE 3. CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS:
-------------------------------------------------
Cash and cash equivalents include highly liquid investments purchased
with remaining maturities of less than ninety days. At September 30, 1997 and
December 31, 1996, all of the Company's short-term investments are classified as
available for sale. Therefore, any unrealized gains or losses should be
presented in a separate component of stockholders' equity. At both September 30,
1997 and December 31, 1996 there were no significant unrealized gains or losses.
Investments are held at market value and at September 30, 1997 and
December 31, 1996 were classified as short-term. Cash, cash equivalents and
investments, consisted of the following:
December 31, September 30,
------------ -------------
1996 1997
---- ----
CASH AND CASH EQUIVALENTS:
Money market funds and demand accounts $ 5,447,000 $ 2,526,000
U.S. government securities 6,313,000 4,492,000
Repurchase agreements 2,092,000 1,614,000
Commercial paper 1,736,000 486,000
----------- -----------
15,588,000 9,118,000
----------- -----------
INVESTMENTS:
U.S. government securities 3,497,000 1,148,000
Bank Certificate of Deposit - 250,000
Commercial paper 1,738,000 -
----------- -----------
5,235,000 1,398,000
----------- -----------
$20,823,000 $10,516,000
=========== ===========
-5-
NOTE 4. ACCOUNTS RECEIVABLE:
-------------------
December 31, September 30,
1996 1997
---------------- ------------------
Trade:
Billed $ 17,548,000 $ 22,972,000
Unbilled 10,590,000 15,859,000
Allowance for doubtful accounts (524,000) (629,000)
---------------- ----------------
$ 27,614,000 $ 38,202,000
================ ================
NOTE 5. EARNINGS PER SHARE ("EPS"):
--------------------------
Statement of Financial Accounting Standards No. 128 ("SFAS 128"),
"Earnings per Share," which supersedes Accounting Principles Board Opinion No.
15 ("APB 15"), "Earnings per Share," was issued February, 1997. SFAS 128
requires dual presentation of basic and diluted EPS for complex capital
structures on the face of the income statement. Basic EPS is computed by
dividing income by the weighted-average number of common shares outstanding for
the period. Diluted EPS reflects the potential dilution from the exercise or
conversion of securities into common stock, such as stock options. SFAS 128 is
required to be adopted for year-end 1997; earlier application is not permitted.
For the nine months ended September 30, 1997 and 1996, and for the three months
then ended, the basic and diluted EPS measured under SFAS 128 is not materially
different from primary and fully-diluted EPS calculated under APB 15.
For the nine-months ended September 30, 1997 and September 30, 1996,
common stock equivalents are antidilutive and have not been considered in the
net loss per share computations. For the three months ended September 30, 1997
and 1996, shares used in calculating earnings per share include dilutive common
stock equivalents--options, warrants and convertible preferred stock.
NOTE 6. MERGER WITH PHARMACO PTY., LTD. ("PPL"):
----------------------------------------
On May 5, 1997, the Company acquired all of the outstanding shares of
stock of PPL in exchange for 575,000 shares of the Company's common stock. PPL
is a provider of clinical trial, regulatory, data management and health
economics services in Australia and New Zealand. PPL has been integrated with
the Company's existing Australian operations. This merger was accounted for as a
pooling of interests. Upon final analysis, it has been determined that this
transaction is not material to the Company's financial results taken as a whole,
and as such, prior period financial statements have not been retroactively
restated in conformity with Accounting Principles Board Opinion No. 16,
"Business Combinations." The results of operations of PPL have been included in
the consolidated operating results from the effective date of the merger. The
$176,000 of costs associated with this merger have been charged to earnings as a
separate component of continuing operations.
-6-
NOTE 7. BANK LOANS:
-----------
In August, 1997, the Company renegotiated its banking relationship. The
Company added a $7,000,000 term loan facility and renewed the existing
$5,000,000 credit facility. The $7,000,000 loan is comprised of four term loans
bearing interest at 7.90% to 8.05% with terms of 36 to 60 months. As of
September 30, 1997, the balance outstanding under these new loans was
$6,064,000. The Company is using the term loan proceeds to finance new leasehold
improvements and new capital equipment for the Pharmaceutics Division and to
enhance the Company's information systems infrastructure. As of September 30,
1997, the balance outstanding under the previously existing credit facility was
$1,094,000.
NOTE 8. DISCONTINUED OPERATIONS:
------------------------
On June 21, 1997, the Company closed the software commercialization
business unit of Resources Biometrics, Inc. ("RBI"), a wholly-owned subsidiary
of the Company. Accordingly, all operating results have been reclassified from
continuing operations to discontinued operations. This unit recorded a net loss
of $607,000 for the nine-months ended September 30, 1997, all of which were
incurred in the first half of 1997. In addition, a loss on the disposal of this
unit of $1,547,000 has been recorded. For the three- and nine- month periods
ended September 30, 1996, $175,000 of operating losses have been reclassified
from continuing operations to discontinued operations. At the time of the
acquisition of RBI, approximately 25% of the purchase price was allocated to the
software commercialization business unit. The majority of the purchase price
allocation was to the service portion of this business, which has given the
Company a viable and active CRO presence on the West Coast. The loss on disposal
is comprised mainly of severance, software asset write-offs, contract completion
costs and future rent related to abandoned office space. The remaining
liabilities related to the loss on disposal at September 30, 1997 are $752,000
and are included in "Other accrued expenses" on the consolidated balance sheet
NOTE 9. RESTRUCTURING CHARGES:
---------------------
In June, 1997, the Company implemented a restructuring plan for the
International CRO. The Company has recorded a one-time restructuring charge of
$1,078,000, consisting primarily of termination benefits for fourteen employees
and an accrual for lease-related charges. As of September 30, 1997, seven
employees have been terminated and $127,000 of termination benefits have been
paid. In addition, lease-related costs of $69,000 have been paid.
-7-
Item 2. Management's Discussion and Analysis of Financial
-------------------------------------------------
Condition and Results of Operations
-----------------------------------
Results of Operations
Three months ended September 30, 1997 versus the three months ended September
30, 1996
IBAH, Inc.
Consolidated Statements of Operations
(amounts in thousands)
(unaudited)
For the Three Months Ended
September 30,
-----------------------------------------------
1996 (1)
1996 Restated 1997
----------- ----------- ----------------
Revenues $ 20,454 $ 20,454 $ 33,575
Less-Reimbursed costs 5,369 5,369 10,511
----------- ----------- ----------------
Net revenues 15,085 15,085 23,064
Operating expenses:
Direct 7,564 7,564 12,376
Selling, general and administrative 6,957 6,957 9,681
Restructuring costs - - -
Non-recurring item-Acquired
Research and development 510 - -
----------- ----------- ----------------
Operating income 54 564 1,007
Interest income (expense), net 161 161 (27)
----------- ----------- ----------------
Income from continuing operations before taxes 215 725 980
Income taxes - - 271
----------- ----------- ----------------
Income from continuing operations 215 725 709
Loss from discontinued operations (175) - -
=========== =========== ================
Net income $ 40 $ 725 $ 709
=========== =========== ================
(1) Restated to exclude one-time charges for acquired research and development
related to the RBI acquisition and the discontinued results from the RBI
software commercialization business unit.
Revenues
- --------
Revenues for the three months ended September 30, 1997 were
$33,575,000, an increase of 64.1% over the same period in 1996. Approximately
half of the increase was due to organic growth in all business segments, with
the remainder principally due to The Hardardt Group ("THG") acquisition on
October 1, 1996.
Reimbursed costs
- ----------------
Reimbursed costs were $10,511,000 for the quarter ended September 30,
1997, or 31.3% of total revenues as compared to 26.2% for the comparable period
in 1996. The increase as a percentage of total revenues is a result of a change
of mix in the business from period to period, whereby more revenue was
recognized from contracts where pass-through costs are reimbursed by clients.
-8-
Net revenues
- ------------
Net revenues for the third quarter of 1997 were $23,064,000, an
increase of 52.9% as compared to the third quarter of 1996, of which 20.0% was
due to internal growth without acquisitions. Increases in revenues were recorded
in the US CRO (up 81.2%, 20.4% of which was organic growth), in the
International CRO (up 3.7%) and in Pharmaceutics (up 69.7%).
Direct expenses
- ---------------
Direct expenses for the third quarter of 1997 were $12,376,000, or
53.7% of net revenues, as compared to 50.1% in the third quarter of 1996. The
increase in direct expenses as a percentage of net revenues from year to year
was due to (1) the mix effect in the US CRO where clinical monitoring revenues
increased as a percentage of revenues, (2) the International CRO performance
where revenues declined from 1996 to a point where productivity was negatively
impacted and (3) the Pharmaceutics division's initial phase of facility
expansion. Direct expenses include all compensation and other direct expenses
associated with revenue producing departments.
Selling, general & administrative
- ---------------------------------
Selling, general and administrative expenses for the third quarter of
1997 were $9,681,000, or 42.0% of net revenues, as compared to 46.1% for the
same period in 1996. The improvement was due principally to the US CRO business
where selling, general and administrative expenses as a percentage of net
revenues decreased from 39.0% in 1996 to 35.9% in 1997. The US CRO showed this
improvement because the revenue volume for this business has continued to grow
more quickly than its infrastructure needs.
Non-recurring item-Acquired research and development
- ----------------------------------------------------
There was no acquired research and development for the three-months
ended September 30, 1997. For the comparable 1996 period, the acquisition of RBI
was concluded in July, 1996 and was treated as a purchase for accounting
purposes. The $510,000 non-recurring charge to earnings represents the portion
of the RBI purchase price allocated to software research and development.
Interest income, net of interest expense
- ----------------------------------------
Net interest expense for the third quarter of 1997 was $27,000 as
compared to net interest income of $161,000 in the comparable 1996 period. The
change was due to a decrease in cash balances and the addition of a $7,000,000
term loan, of which a total of $6,064,000 was drawn against the loan as of
September 30, 1997.
Discontinued Operations
- -----------------------
There were no charges to discontinued operations for the three-month
period ended September 30, 1997. For the three-month period ended September 30,
1996, $175,000 of operating results of the discontinued RBI software
commercialization business unit have been reclassified from continuing
operations to discontinued operations.
-9-
Net Income
- ----------
Net income for the quarter ended September 30, 1997 was $709,000 or
$.03 per share as compared to a net income in the comparable 1996 period of
$40,000 or break-even per share. Net income, excluding the one-time charges for
acquired research and development from the RBI acquisition and the operating
results related to the discontinued RBI software commercialization business was,
$725,000 or $.03 per share for the quarter ended September 30, 1996.
Nine months ended September 30, 1997 versus the nine months ended September 30,
1996
IBAH, Inc.
Consolidated Statements of Operations
(amounts in thousands)
(unaudited)
For the Nine Months Ended
September 30
------------------------------------------------------------------
1997 (2)
1996(1) (As
1996 (As Restated) 1997 Restated)
--------------- ------------ -------------- -------------
Revenues $ 55,966 $ 55,966 $ 91,513 $ 91,513
Less-Reimbursed costs 14,302 14,302 28,144 28,144
--------------- ------------ -------------- -------------
Net revenues 41,664 41,664 63,369 63,369
Operating expenses:
Direct 21,325 21,325 34,191 34,191
Selling, general and administrative 20,003 20,003 27,267 27,267
Restructuring costs - - 1,078 -
Non-recurring item-Acquired
research and development 510 - - -
--------------- ------------ -------------- -------------
Operating income (loss) (174) 336 833 1,911
Merger costs - (176) -
Interest income (expense), net 299 299 266 266
--------------- ------------ -------------- -------------
Income from continuing operations before taxes 125 635 923 2,177
Income taxes - - 763 763
--------------- ------------ -------------- -------------
Income from continuing operations 125 635 160 1,414
Loss from discontinued operations (175) - (2,154) -
=============== ============ ============== =============
Net income (loss) $ (50) $ 635 $(1,994) $ 1,414
=============== ============ ============== =============
(1) Restated to exclude one-time charges for acquired research and development
related to the RBI acquisition and operating results of the discontinued
RBI software commercialization business unit.
(2) Restated to exclude one-time charges for the cost to restructure the
operations of the International CRO, for costs related to the PPL merger
and for the disposal of the RBI software commercialization business unit.
Revenues
- --------
Revenues for the nine months ended September 30, 1997 were $91,513,000,
an increase of 63.5% over the same period in 1996.
Reimbursed costs
- ----------------
Reimbursed costs were $28,144,000 or 30.8% of total revenues for the
nine-month period in 1997 as compared to 25.6% for the nine month period in
1996. The increase as a percentage of total revenues is a result of a change of
mix in the business from period to period, whereby more revenue was recognized
from contracts where pass-through costs are reimbursed by clients.
-10-
Net revenues
- ------------
Net revenues for the nine-month period ended September 30, 1997 were
$63,369,000, an increase of 52.1% over the nine month period in 1996, of which
21.3% was due to internal growth without acquisitions. Increases in revenues
were recorded in the US CRO (up 98.2%, 31.9% of which was organic growth) and
Pharmaceutics (up 71.0%) being partially offset by a decrease in International
CRO revenues (down 12.0%).
Direct expenses
- ---------------
Direct expenses for the nine months of 1997 were $34,191,000, or 54.0%
of net revenues, as compared to 51.2% for the same period in 1996. The increase
in direct expenses as a percentage of net revenues from year to year was due to
the (1) mix effect in the US CRO where clinical monitoring revenues increased as
a percentage of revenues, (2) the International CRO performance where revenues
declined from 1996 to a point where productivity was negatively impacted and (3)
the Pharmaceutics division's initial phase of facility expansion. Direct
expenses include all compensation and other direct expenses associated with
revenue producing departments.
Selling, general & administrative
- ---------------------------------
Selling, general and administrative expenses for the nine months ended
September 30, 1997 were $27,267,000 or 43.0% of net revenues, as compared to
48.0% for the same period in 1996. The improvement was due principally to the US
CRO business where selling, general and administrative expenses as a percentage
of net revenues decreased from 43.5% in 1996 to 36.1% in 1997. The US CRO showed
this improvement because the revenue volume for this business has continued to
grow more quickly than its infrastructure needs.
Restructuring Costs
- -------------------
In June, 1997, the Company implemented a restructuring plan for the
International CRO. The Company has recorded a one-time restructuring charge of
$1,078,000, consisting primarily of termination benefits for fourteen employees
and an accrual for lease-related charges. As of September 30, 1997, seven
employees have been terminated and $127,000 of termination benefits have been
paid. In addition, lease-related costs of $69,000 have been paid. There were no
restructuring costs for the nine months ended September 30, 1996.
Non-recurring item-Acquired research and development
- ----------------------------------------------------
There was no acquired research and development for the nine-months
ended September 30, 1997. For the comparable 1996 period, the acquisition of RBI
was concluded in July, 1996 and was treated as a purchase for accounting
purposes. The $510,000 non-recurring charge to earnings represents the portion
of the RBI purchase price allocated to software research and development.
Merger Costs
- ------------
The merger costs incurred during the nine months ended September 30, 1997 relate
entirely to the merger with Pharmaco Pty. Ltd. ("PPL"), an Australian based CRO.
The costs related to this transaction have been charged to earnings as this
merger is accounted for as a pooling of interests.
-11-
Interest income, net of interest expense
- ----------------------------------------
Net interest income for nine months ended September 30, 1997 was
$266,000 as compared to $299,000 in the comparable 1996 period. The change was
due to changes in cash balances and the addition of a $7,000,000 term loan, of
which a total of $6,064,000 was drawn against the loan as of September 30, 1997.
Discontinued Operations
- -----------------------
RBI's software commercialization business unit was closed on June 21,
1997. Accordingly, all operating results have been reclassified from continuing
operations to discontinued operations. This unit has recorded a net loss of
$607,000 for nine months ended September 30, 1997, all of which was incurred
during the six months ended June 30, 1997 and a net loss of $175,000 for the
nine months ended September 30, 1996. In addition, a loss on the disposal of
this unit of $1,547,000 has been recorded in the six months ended June 30, 1997.
This loss on disposal is comprised mainly of severance, software asset
write-offs, contract completion costs and future rent related to abandoned
office space. The remaining liabilities related to the loss on disposal at
September 30, 1997 are $752,000 and are included in "Other accrued expenses" on
the consolidated balance sheet.
Net Income (loss)
- -----------------
Net income, excluding the one-time charges for the discontinued RBI
software commercialization business unit, the PPL merger costs and the
International CRO restructuring, was $1,414,000 or $.05 per share for the nine
months ended September 30, 1997 compared to a net income in the comparable 1996
period of $635,000 or $.03 per share. With the one-time charges included, net
loss for the nine months ended September 30, 1997 was $1,994,000 or $.09 per
share as compared to a net loss in the comparable 1996 period of $50,000 or
break-even per share.
Project backlog
- ---------------
The Company is having success in acquiring new business in the US CRO,
International CRO and Pharmaceutics Divisions. However, due to the uncertainty
and fluctuations that may occur in contract backlog, the Company, consistent
with other major CROs, does not report contract backlog.
Divisional Breakdown (third quarter 1997 versus third quarter 1996)-(See Page
- -----------------------------------------------------------------------------
14)
- ---
US CRO
Net revenues of the US CRO increased by 81.2%, (20.4% without
acquisitions) on a comparable quarter basis. Operating income was $1,903,000 for
the third quarter of 1997, a 297.3% increase over the comparable quarter of 1996
including one-time charges, reflecting increased revenue growth and productivity
improvements for this Division. The US CRO continues its trend of obtaining
strong new business commitments.
International CRO
International net revenues increased by 3.7% from the third quarter of
1996 to the third quarter of 1997. On a sequential quarter basis, net revenues
increased 12.7% from the second quarter. Additionally, operating losses
decreased by 19.4% quarter over quarter due to improved revenue volume.
-12-
The sequential improvement of net revenues and operating losses
continues the favorable trend initiated in the second quarter of 1997. In
addition, the International CRO continues the trend of obtaining new business
commitments.
Savings realized from the implementation of the second quarter
restructuring program resulted in flat indirect growth third quarter 1997 to
second quarter 1997. Additionally, indirect expenses are expected to continue to
grow at a slow rate for the remainder of the year.
International has continued adding strong management talent to its
portfolio to further position the business for future growth.
Pharmaceutics
Pharmaceutics net revenues increased to $2,777,000 a 69.7% increase
over the third quarter of 1996. The continued increase in revenue volume
favorably impacted operating income which improved 39.8% to $376,000 in the
quarter ended September 30, 1997 over the comparable quarter of 1996. Overall
margins declined sequentially quarter to quarter due to incremental expenses,
related to the initial phase of facility expansion, that included new production
space, staffing and equipment, increasing overall capacity. Operating margins
are expected to improve in the fourth quarter. New business commitments continue
to be robust.
Liquidity and Capital Resources
- -------------------------------
As of September, 1997, the Company had cash, cash equivalents and
short-term investments of $10,516,000 as compared to $20,823,000 as of December
31, 1996. The decline in cash from December 31, 1996 to September 30, 1997 was
due to the timing of collections of account receivables, net of customer
deposits, losses in the International CRO, the capital investment related to the
new Pharmaceutics facility and the global Information Technology infrastructure.
These factors were offset by proceeds from the new bank term facility (see
below). Working capital as of September 30, 1997 was $8,994,000 as compared to
$9,206,000 as of December 31, 1996. The decline in working capital from year-end
1996 to September 30, 1997 was due principally to increased capital spending for
the new Pharmaceutics facility, offset by the term loan, and the impact of the
one-time restructuring and discontinued operations charges.
In August, 1997 the Company added a $7,000,000 term loan facility and
renewed the existing $5,000,000 credit facility. The $7,000,000 loan is
comprised of four term loans bearing interest at 7.90% to 8.05% with terms of 36
to 60 months. As of September 30, 1997, the balance outstanding under these new
loans was $6,064,000. The Company is using the term loan proceeds to finance new
leasehold improvements and new capital equipment for the Pharmaceutics Division
and to enhance the Company's information systems infrastructure. As of September
30, 1997, the balance outstanding under the previously existing credit facility
was $1,094,000.
Although the Company does not believe that it requires financing for
working capital purposes, it may seek additional cash infusions for expansion of
operations, for strategic acquisitions or for competitive reasons
Based on the foregoing and other factors, and while there can be no
assurance that external financing will be available on terms acceptable to the
Company, the Company believes that it has, or has access to, adequate working
capital to meet its strategic objectives and fund its operations for the
foreseeable future.
This document contains "forward-looking" statements. These statements
carry risks and uncertainties that could cause the Company's actual results to
differ materially from the results
-13-
discussed in the forward-looking statements. Factors that might cause such a
difference include, but are not limited to, the ability to increase sales or
revenue growth at or above market rates; the success of the International CRO
restructuring; the Company's success in obtaining new business; the loss or
delay of contracts for regulatory or other reasons; a letter of intent on a
substantial project that does not materialize into a signed contract for a
material portion of that project; risks associated with acquisitions; the degree
of success of the strategic decision to discontinue the RBI software
commercialization business unit; and fluctuations in foreign currencies.
-14-
For purposes of the following discussion, the following table presents the
results of operations on a divisional level (in thousands):
IBAH, Inc.
International
Divisional Statements of Operations US Clinical Services Clinical Services
--------------------------------------------------------
(unaudited) Three Months Ended September 30,
--------------------------------------------------------
1996 (2)
1996 (1) (As Restated) 1997 1996 1997
-------- ------------- ---- ---- ----
Net revenues $ 8,183 $ 8,183 $ 14,828 $ 5,266 $ 5,459
Operating expenses:
Direct expenses 4,001 4,001 7,601 2,627 3,230
Selling, general & administrative 3,193 3,193 5,324 3,333 3,501
Restructuring costs - - - - -
Non-recurring item-Acquired
research and development 510 - - - -
--------------------------------- ---------------------
Operating income (loss) $ 479 $ 989 $ 1,903 $ (694) $(1,272)
================================= =====================
Divisional Statements of Operations Pharmaceutics IBAH, Inc. Consolidated
---------------------- ------------------------------
(unaudited) Three Months Ended September 30,
-------------------------------------------------------
1996 (2)
1996 1997 1996 (1) (As Restated) 1997
---- ---- -------- ------------- ----
Net revenues $ 1,636 $ 2,777 $ 15,085 $ 15,085 $ 23,064
Operating expenses:
Direct expenses 936 1,545 7,564 7,564 12,376
Selling, general & administrative 431 856 6,957 6,957 9,681
Restructuring costs - - - - -
Non-recurring item-Acquired
research and development - - 510 - -
------------------- ---------------------------------
Operating income (loss) $ 269 $ 376 $ 54 $ 564 $ 1,007
=================== =================================
The information presented in the above table does not purport to be
indicative of future results of operations.
(1) Excludes the results of the discontinued RBI software commercialization
business.
(2) Excludes one-time charges for acquired research and development charges
related to the RBI acquisition, and the discontinued results from the RBI
software commercialization business.
-15-
For purposes of the following discussion, the following table presents the
results of operations on a divisional level (in thousands):
IBAH, Inc.
Divisional Statements of Operations US Clinical Services International Clinical Services
------------------------------------ -----------------------------------
Nine Months Ended September 30,
-------------------------------------------------------------------------
1996 (1)(2) 1997 (3)(4)
1996 (1) (As Restated) 1997 1996 1997 (3) (As Restated)
-------- ------------- ---- ---- -------- -------------
Net revenues $ 21,065 $ 21,065 $ 41,745 $ 16,396 $ 14,436 $ 14,436
Operating expenses:
Direct expenses 10,693 10,693 21,343 8,179 8,879 8,879
Selling, general & administrative 9,157 9,157 15,076 9,560 10,050 10,050
Restructuring costs - - - - 1,078 -
Non-recurring item-Acquired
research and development 510 - - - - -
------------------------------------ ------------------------------------
Operating income (loss) $ 705 $ 1,215 $ 5,326 $ (1,343) $ (5,571) $ (4,493)
==================================== ====================================
Divisional Statements of Operations Pharmaceutics IBAH, Inc. Consolidated
--------------- --------------------------------------------------
Nine Months Ended September 30,
-------------------------------------------------------------------------
1996 (1)(2) 1997 (3)(4)
1996 1997 1996 (1) (As Restated) 1997 (2) (As Restated)
---- ---- -------- ------------- -------- -------------
Net revenues $ 4,203 $ 7,188 $ 41,664 $41,664 $ 63,369 $ 63,369
Operating expenses:
Direct expenses 2,453 3,969 21,325 21,325 34,191 34,191
Selling, general & administrative 1,286 2,141 20,003 20,003 27,267 27,267
Restructuring costs - - - - 1,078 -
Non-recurring item-Acquired
research and development - - 510 - - -
------------------ -----------------------------------------------------
Operating income (loss) $ 464 $ 1,078 $ (174) $ 336 $ 833 $ 1,911
================== =====================================================
The information presented in the above table does not purport to be
indicative of future results of operations.
(1) Excludes the results of the discontinued RBI software commercialization
business.
(2) Excludes one-time charges for acquired research and development charges
related to the RBI acquisition, and the results of the discontinued RBI
software commercialization business.
(3) Amounts include the operations of Pharmaco Pty. Ltd from the date of the
Merger on May 5, 1997.
(4) Excludes one-time charges for the cost to restructure the operations of
the International CRO. Amounts include the operations of Pharmaco Pty.
Ltd from the date of the Merger on May 5, 1997.
-16-
Part II - Other Information
Item 1. Legal Proceedings
None.
Item 2. Changes in Securities
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Submission of Matters to a Vote of Security Holders
None.
Item 5. Other Information
None.
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits
11 Computation of Net Income (Loss) per Common Share.
27 Financial Data.
(b) Reports on Form 8-K
None.
-17-
Signatures
Pursuant to the requirements of Section 13 or 15 (d) of the Securities
Exchange Act of 1934, as amended, the Registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized.
IBAH, INC.
Date: November 13, 1997 By /s/ Geraldine A. Henwood
------------------------
Geraldine A. Henwood
Chief Executive Officer
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, as amended, this Report has been signed below by the
following persons on behalf of the Registrant and in the capacities and on the
dates indicated.
Date: November 13, 1997 By: /s/ Geraldine A. Henwood
------------------------
Geraldine A. Henwood
Chief Executive Officer
(Principal Executive Officer)
Date: November 13, 1997 By: /s/ Cornelius H. Lansing, II
----------------------------
Cornelius H. Lansing
Chief Financial Officer
(Principal Financial Officer)
-18-